Abstract:A series of 8‐(piperazin‐1‐yl)imidazo[1,2‐a] pyrazine derivatives were designed and synthesized as acetylcholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease. Among them, compound 1 (eeAChE, IC50=0.55 μM, eqBuChE, IC50=16.04 μM) was found to have excellent inhibitory activity. Meanwhile compound 1 exhibited antioxidant activity (IC50=136.66 μM). A series of 8‐(piperazin‐1‐yl) imidazo [1,2‐a] pyrazine derivatives were designed and synthesized as acetylcholinesterase inhibitors (AChEIs) and antioxidants for the treatment of Alzheimer's disease (AD). Moreover, the biological evaluation results demonstrated that these synthesized compounds exhibited moderate inhibitory activities toward acetylcholinesterase (AChE) and radical scavenging activities. Among them, the compound with the strongest inhibitory activity against AChE had an IC50 value of 0.55 μM, which was higher than that of galantamine as the reference compound (IC50 value=5.01 μM). The compound with the strongest antioxidant activity had an IC50 value of 57.94 μM, which was lower than that of the ascorbic acid (IC50 value=25.70 μM) as the control drug. Furthermore, the results of molecular docking studies indicated that the compound could simultaneously bind to both catalytic active site (CAS) and peripheral anionic site (PAS) of AChE, which was consistent with the mixed inhibition pattern shown by enzyme kinetic studies. The interaction's stability was also assessed using a conventional atomistic 100 ns dynamics simulation study, which revealed the conformational stability of representative compound in the cavity of the AChE. In addition, the molecular properties of all compounds were predicted online through the SwissADME, and most compounds matched the properties of most orally administered drugs. Based on the biological activity and molecular properties, 8‐(piperazin‐1‐yl) imidazo[1,2‐a] pyrazine derivatives as AChEI were valuable for further development.

Design, synthesis and evaluation of N-arylmethylamide derivatives as cholinesterase inhibitors

Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease

Design, Synthesis and Evaluation of 8‐(Piperazin‐1‐yl) Imidazo[1,2‐a]Pyrazine Derivatives as Acetylcholinesterase Inhibitors and Antioxidants

Design, Synthesis, and Biological Evaluation of a New Series of Biphenyl/Bibenzyl Derivatives Functioning As Dual Inhibitors of Acetylcholinesterase and Butyrylcholinesterase

Design, synthesis and evaluation of imidazo[1,2-a]pyrazin-8(7H)-one derivatives as acetylcholinesterase inhibitors and antioxidants

Novel Thiadiazole Derivatives as Potential Anti‐Alzheimer Agent: Synthesis, Activity of Molecular Interactions and their in Silico Assessment

Discovery, Structure-Based Modification, In Vitro , In Vivo , and In Silico Exploration of m -Sulfamoyl Benzoamide Derivatives as Selective Butyrylcholinesterase Inhibitors for Treating Alzheimer’s Disease

Design, Synthesis, and Evaluation of Acetylcholinesterase and Butyrylcholinesterase Dual-Target Inhibitors Against Alzheimer’s Diseases

Design, Synthesis, Biological Evaluation and Molecular Modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4yl)methyl)benzo[d][1,3] Dioxole-5-carboxamides As Selective Butyrylcholinesterase Inhibitors.

Design, Synthesis, In Vitro And In Vivo Evaluation Of Benzylpiperidine-Linked 1,3-Dimethylbenzimidazolinones As Cholinesterase Inhibitors Against Alzheimer'S Disease

Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential anti-Alzheimer's Disease Agents.

Synthesis and biological evaluation of substituted acetamide derivatives as potential butyrylcholinestrase inhibitors

Synthesis of Flavonoid/Sulfonamide Hybrid Molecules as Potential Inhibitors of Cholinesterases: In Vitro, Molecular Docking, Molecular Dynamic and DFT Studies

Discovery, Structure-Based Modification, in Vitro, in Vivo, and in Silico Exploration of M-Sulfamoyl Benzoamide Derivatives As Selective Butyrylcholinesterase Inhibitors for Treating Alzheimer's Disease.

Design, Synthesis, and Bioevaluation of Indole Core Containing 2-Arylidine Derivatives of Thiazolopyrimidine As Multitarget Inhibitors of Cholinesterases and Monoamine Oxidase A/B for the Treatment of Alzheimer Disease

Design, synthesis, biological evaluation, and molecular dynamics of novel cholinesterase inhibitors as anti‐Alzheimer's agents

Design, Synthesis, and Bioevaluation of Benzamides: Novel Acetylcholinesterase Inhibitors with Multi-Functions on Butylcholinesterase, Aβ Aggregation, and Β-Secretase.

Design, Synthesis, and Biological Evaluation of Dual-Target Inhibitors of Acetylcholinesterase (ache) and Phosphodiesterase 9A (PDE9A) for the Treatment of Alzheimer's Disease

Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease.

Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer's disease.

Design, Synthesis and Biological Evaluation of Dual Acetyl Cholinesterase and Beta-Secretase Inhibitors in Treatment for Alzheimer's Disease.